Comparative Efficacy and Safety of Octreotide, Lanreotide, and Pasireotide in Autosomal Dominant Polycystic Kidney Disease and Polycystic Liver Disease: A Network Meta-Analysis With Real-World Evidence From the FDA Adverse Event Reporting System Database.
The online reader was unable to display this document directly. This may occur if the repository host is temporarily unreachable, or if security restrictions (CORS) prevent embedded viewing.